LNA-i-miR-221 activity in Colorectal Cancer: A reverse translational Investigation

Ali Asad,Grillone Katia,Ascrizzi Serena,Caridà Giulio,Fiorillo Lucia,Ciliberto Domenico,Staropoli Nicoletta,Tagliaferri Pierosandro,Tassone Pierfrancesco,Di Martino Maria Teresa
DOI: https://doi.org/10.1016/j.omtn.2024.102221
IF: 10.183
2024-05-23
Molecular Therapy — Nucleic Acids
Abstract:Colorectal cancer (CRC) is one of the most common malignancy and a relevant cause of cancer-related deaths worldwide. Dysregulation of microRNAs (miRNAs) expression has been associated with the development and progression of various cancers, including CRC. Among them, miR-221 emerged as an oncogenic driver, whose high expression is associated with poor patient prognosis. The present study was conceived to investigate the anti-CRC activity of miR-221 silencing based on clinical early data achieved from a first-in-human study by our group. Going back from bedside to bench, we demonstrated that LNA-i-miR-221 reduces cell viability, induces apoptosis in vitro , and impairs tumor growth in pre-clinical in vivo models of CRC. Importantly, we disclosed that miR-221 directly targets TP53BP2, which, together with TP53INP1, is known as positive regulator of TP53 apoptotic pathway. We found that i) both these genes are overexpressed following miR-221 inhibition, ii) the strong anti-tumor activity of LNA-i-miR-221 was selectively observed on TP53 wild type cells, iii) this activity was reduced in the presence of the TP53-inhibitor Pifitrin-α. Our data pave the way to further investigations on TP53 functionality as marker predictive of response to miR-221 silencing which might be relevant for clinical applications.
medicine, research & experimental
What problem does this paper attempt to address?